Pooled analysis of single-dose oritavancin in the treatment of acute bacterial skin and skin-structure infections caused by Gram-positive pathogens, including a large patient subset with methicillin-resistant Staphylococcus aureus
详细信息 查看全文
- 作者：G. Ralph Coreya ; Francis F. Arhinb ; Matthew A. Wiklerc ; 1 ; Daniel F. Sahmd ; Barry N. Kreiswirthe ; José ; R. Mediavillae ; Samantha Goodc ; 2 ; Claude Fisetc ; Hai Jiangc ; 3 ; Greg Moeckb ; greg.moeck@themedco.com" class="auth_mail" title="E-mail the corresponding author ; Heidi Kablerf ; Sinikka Greeng ; William O'Riordanh ; on behalf of the SOLO I ; SOLO II Investigators
- 关键词：Acute bacterial skin infection ; Single-dose treatment ; Clinical efficacy ; MRSA ; Lipoglycopeptide ; Phase 3 study
- 刊名：International Journal of Antimicrobial Agents
- 出版年：2016
- 出版时间：November 2016
- 年：2016
- 卷：48
- 期：5
- 页码：528-534
- 全文大小：274 K
文摘
- •
Phase 3 acute bacterial skin and skin-structure infection (ABSSSI) studies SOLO I and SOLO II included 405 patients with confirmed MRSA.
- •
Clinical response rates by pathogen were similar for oritavancin and vancomycin.
- •
Clinical response in Staphylococcus  aureus patients was not impacted by spa type or pvl gene.
- •
Oritavancin exhibited potent in vitro activity against all baseline pathogens.
- •
Oritavancin provides a single-dose alternative to multidose vancomycin for ABSSSI.